Bio-Path (BPTH) announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on the extent of its ...

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its ...

A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase ...

5) and to study its enzymatic properties, and soon thereafter, Miguel Ondetti and I began a fruitful collaborative effort to discover or design potent and specific inhibitors of ACE. The modern ...

Target identification is the process of identifying the direct molecular target – for example protein or nucleic acid – of a small ... highly selective kinase inhibitors remains challenging.

Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...